Formulation, development and characterization of topical organogel of mometasone furoate for the treatment of skin disease

Topical glucocorticoid formulations are widely used for effective treatment and control of a variety of dermatoses. Mometasone furoate is a medium potency, synthetic, non-fluorinated topical corticosteroid, indicated for the relief of inflammatory and pruritic manifestations of corticosteroid responsive dermatoses including psoriasis. The percutaneous absorption increases risk associated with systemic absorption of topically applied formulation. Controlled release of the drug to the skin could reduce the side effects while reducing percutaneous absorption. Organogels are semi-solid materials, in which an organic phase is immobilized by a three-dimensional network composed of self-organized system, forming the aqueous phase. The present study deals with the preparation and evaluation of a pluronic lecithin organogel gel containing mometasone furoate for transdermal delivery. Blank pluronic lecithin organogel were prepared using ricinoleic acid as the oil phase. Formulation, Development and Characterization of Topical Organogel of Mometasone Furoate was carried out and evaluated for the treatment of Skin Disease. The absorption maxima of mometasone furoate were determined by running the spectrum of drug solution in double beam ultraviolet spectrophotometer (Labindia UV 3000+) using concentration range of 5-25μg/ml mometasone furoate in 7.4 phosphate buffers. The IR spectrum of sample drug and drug with excipients shows the peak values which are characteristics of the drug. The formulated gel formulation was evaluated with parameter appearance, consistency, drug content pH, viscosity, spreadability, in-vitro release test, washability, extrudability study and stability studies. FT-IR studies revealed no interaction between the drug and excipients. Selected organogels (F3) showed a drug content of 99.45±0.14% and drug release of 99.12 % in10 hrs. The results suggest that the developed organogels formulation containing mometasone furoate can be of actual value for improving the clinical effectiveness in the treatment of psoriasis.